Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 1/20 | 0.60 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.55 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.54 |
| ▸ | ROCK1 | Q13464 | 4/20 | 0.54 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.54 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.54 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.54 |
| ▸ | PAK4 | O96013 | 1/20 | 0.54 |
| ▸ | PRKCG | P05129 | 1/20 | 0.54 |
| ▸ | CDK1 | P06493 | 1/20 | 0.54 |
| ▸ | PRKACA | P17612 | 1/20 | 0.54 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.54 |
| ▸ | CDK2 | P24941 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | AKT1 | P31749 | 1/20 | 0.54 |
| ▸ | AKT2 | P31751 | 1/20 | 0.54 |
| ▸ | CLK2 | P49760 | 1/20 | 0.54 |
| ▸ | GSK3A | P49840 | 1/20 | 0.54 |
| ▸ | GSK3B | P49841 | 1/20 | 0.54 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL117597 | 1.00 | RIPK1 (0.60) | RIPK1EPHX2ROCK2ROCK1MAPK13 | |
| SCHEMBL3311541 | 1.00 | RIPK1 (0.60) | RIPK1EPHX2ROCK2ROCK1MAPK13 | |
| SCHEMBL6939333 | 0.88 | RIPK1 (0.54) | RIPK1EPHX2ROCK2ROCK1MAPK13 | |
| SCHEMBL4332848 | 0.88 | RIPK1 (0.60) | RIPK1EPHX2ROCK2ROCK1MAPK13 | |
| SCHEMBL28136628 | 0.87 | RIPK1 (0.52) | RIPK1EPHX2ROCK2ROCK1MAPK13 | |
| SCHEMBL4337456 | 0.86 | RIPK1 (0.58) | RIPK1EPHX2ROCK2ROCK1MAPK13 | |
| SCHEMBL21523031 | 0.84 | GPR88 (0.58) | RIPK1GPR88METAP2METAP1 | |
| SCHEMBL21331612 | 0.84 | GPR88 (0.58) | RIPK1GPR88METAP2METAP1 | |
| SCHEMBL21331611 | 0.84 | GPR88 (0.58) | RIPK1GPR88METAP2METAP1 | |
| SCHEMBL21331610 | 0.84 | GPR88 (0.58) | RIPK1GPR88METAP2METAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2006055837-A2 | PROCESS FOR PREPARING OXAZOLIDINE DERIVATIVES | DR. REDDY'S LABORATORIES LTD. (IN) | 2006-05-26 | — | — | WO | claimed |
| EP-4295845-A2 | SOLID FORMS OF THE TARTRATE SALT OF 3-((1R,3R)-1-(2,6-DIFLUORO-4-((1-(3-FLUOROPROPYL)AZETIDIN-3-YL)AMINO)PHENYL)-3-METHYL-1,3,4,9-TETRAHYDRO-2H-PYRIDO[3,4-B]INDOL-2-YL)-2,2-DIFLUOROPROPAN-1-OL, PROCESS FOR THEIR PREPARATION AND METHODS OF THEIR USE IN TREATING CANCERS | F. Hoffmann-La Roche AG (CH) | 2023-12-27 | — | — | EP | disclosed |
| US-11780834-B2 | Solid forms of 3-((1R,3R)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)azetidin-3- yl)amino)phenyl)-3-methyl-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-1-ol and processes for preparing fused tricyclic compounds comprising a substituted phenyl or pyridinyl moiety, including methods of their use | GENENTECH, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-20230219975-A1 | PYRIDO[2,3-B][1,4]OXAZINES OR TETRAHYDROPYRIDO[2,3-B][1,4]OXAZEPINES AS IAP ANTAGONISTS | BEONE MEDICINES I GMBH (CH) | 2023-07-13 | — | — | US | disclosed |
| EP-3810283-B1 | SOLID FORMS OF THE TARTRATE SALT OF 3-((1R,3R)-1-(2,6-DIFLUORO-4-((1-(3-FLUOROPROPYL)AZETIDIN-3-YL)AMINO)PHENYL)-3-METHYL-1,3,4,9-TETRAHYDRO-2H-PYRIDO[3,4-B]INDOL-2-YL)-2,2-DIFLUOROPROPAN-1-OL, PROCESS FOR THEIR PREPARATION AND METHODS OF THEIR USE IN TREATING CANCERS | HOFFMANN LA ROCHE (CH) | 2023-06-14 | — | — | EP | disclosed |
| US-20210300935-A1 | PYRAZOLO-QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | Nerviano Medical Sciences, S.R.L. (IT) | 2021-09-30 | — | — | US | disclosed |
| WO-2021094210-A1 | SUBSTITUTED PYRAZINE CARBOXAMIDE DERIVATIVES AS PROSTAGLANDIN EP3 RECEPTOR ANTAGONISTS | BAYER AKTIENGESELLSCHAFT (DE) | 2021-05-20 | — | — | WO | disclosed |
| EP-3810283-A1 | SOLID FORMS OF 3-((1R,3R)-1-(2,6-DIFLUORO-4-((1-(3-FLUOROPROPYL)AZETIDIN-3-YL)AMINO)PHENYL)-3-METHYL-1,3,4,9-TETRAHYDRO-2H-PYRIDO[3,4-B]INDOL-2-YL)-2,2-DIFLUOROPROPAN-1-OL AND PROCESSES FOR PREPARING FUSED TRICYCLIC COMPOUNDS COMPRISING A SUBSTITUTED PHENYL OR PYRIDINYL MOIETY, INCLUDING METHODS OF THEIR USE | F. Hoffmann-La Roche AG (CH) | 2021-04-28 | — | — | EP | disclosed |
| EP-3793559-A1 | SUBSTITUTED DIHYDROPYRAZOLO PYRAZINE CARBOXAMIDE DERIVATIVES | Bayer Aktiengesellschaft (DE) | 2021-03-24 | — | — | EP | disclosed |
| US-10954234-B2 | Solid forms of 3-((1R,3R)-1-(2,6-difluoro-4-((1-(3- fluoropropyl)azetidin-3-yl)amino)phenyl)-3-methyl-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-1-ol and processes for preparing fused tricyclic compounds comprising a substituted phenyl or pyridinyl moiety, including methods of their use | GENENTECH, INC. (US) | 2021-03-23 | — | — | US | disclosed |
| EP-2396307-A1 | NOVEL AMINO AZAHETEROCYCLIC CARBOXAMIDES | Merck Patent GmbH (DE) | 2011-12-21 | — | — | EP | disclosed |
| CN-102120724-A | 5-amino-4-hydroxy-7-benzyl-8-methylnonanamide derivative, preparation method thereof and application thereof in medicines | JIANGSU HENGRUI MEDICINE CO | 2011-07-13 | — | — | CN | disclosed |
| CN-102060732-A | 5-amino-4-hydroxy-N-aryl azelamide derivatives as well as preparation methods and medical applications thereof | JIANGSU HENGRUI MEDICINE CO | 2011-05-18 | — | — | CN | disclosed |
| WO-2010093419-A1 | NOVEL AMINO AZAHETEROCYCLIC CARBOXAMIDES | MERCK PATENT GMBH (DE) | 2010-08-19 | — | — | WO | disclosed |
| US-20090124605-A1 | Pyrazolo-Quinazoline Derivatives, Process for Their Preparation and Their Use as Kinase Inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2009-05-14 | — | — | US | disclosed |
| US-7482354-B2 | Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2009-01-27 | — | — | US | disclosed |
| US-20070185143-A1 | Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2007-08-09 | — | — | US | disclosed |
| WO-2006055837-A2 | PROCESS FOR PREPARING OXAZOLIDINE DERIVATIVES | DR. REDDY'S LABORATORIES LTD. (IN) | 2006-05-26 | — | — | WO | disclosed |
| US-5589476-A | TREATMENT OF NAUSEA, VOMITING AND GASTROINTESTINAL DISORDERS | SYNTHELABO (FR) | 1996-12-31 | — | — | US | disclosed |
| EP-0646583-A1 | Derivatives of Imidezol-4-yl piperidine, their preparation and use in therapy | SYNTHELABO (FR) | 1995-04-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210300935-A1 | PYRAZOLO-QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | MAP3K5, MAP3K9, MAP4K2 | RIPK1 473/4885EPHX2 4090/4885ROCK2 745/4885 |
| US-20090124605-A1 | Pyrazolo-Quinazoline Derivatives, Process for Their Preparation and Their Use as Kinase Inhibitors | MAP3K5, MAP3K9, MAP4K2 | RIPK1 470/4885EPHX2 4111/4885ROCK2 745/4885 |
| US-20230219975-A1 | PYRIDO[2,3-B][1,4]OXAZINES OR TETRAHYDROPYRIDO[2,3-B][1,4]OXAZEPINES AS IAP ANTAGONISTS | BIRC2, BIRC3, API5 | RIPK1 72/4885EPHX2 4146/4885ROCK2 2659/4885 |
| US-20070185143-A1 | Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors | MAP3K5, MAP3K9, MAP3K19 | RIPK1 427/4885EPHX2 4231/4885ROCK2 723/4885 |
| US-11780834-B2 | Solid forms of 3-((1R,3R)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)azetidin-3- yl)amino)phenyl)-3-methyl-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-1-ol and processes for preparing fused tricyclic compounds comprising a substituted phenyl or pyridinyl moiety, including methods of their use | TP53, DPYD, FLI1 | RIPK1 1386/4885EPHX2 3387/4885ROCK2 1606/4885 |
| US-10954234-B2 | Solid forms of 3-((1R,3R)-1-(2,6-difluoro-4-((1-(3- fluoropropyl)azetidin-3-yl)amino)phenyl)-3-methyl-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-1-ol and processes for preparing fused tricyclic compounds comprising a substituted phenyl or pyridinyl moiety, including methods of their use | TP53, DPYD, FLI1 | RIPK1 1386/4885EPHX2 3387/4885ROCK2 1606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.